Dr Wouter Vogel, radiation oncologist at the Netherlands Cancer Institute, explained that the reason the glands have gone ...

THIS YEAR the Spanish capital, Madrid, provided the backdrop for Europe’s biggest urological event, the 40th Annual European ...

Leading cancer researchers from UC San Francisco presented talks about advances in targeted therapies, cancer genomics, using AI to personalize cancer treatment, improving diagnosis of hard-to-treat ...

Irene Burger highlighted the risk of false positive PSMA PET findings across the prostate, lymph nodes, viscera, and bones, emphasizing the importance of understanding anatomy, lesion morphology, and ...

This approval provides healthcare providers in the Czech Republic with broader access to PSMA-PET [3] imaging, using a clinically validated gallium-based radiopharmaceutical. Illuccix, after ...

MELBOURNE, Australia, April 29, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its prostate cancer PET 1 imaging agent ...

Illuccix, after radiolabelling with gallium-68, is indicated in France for the detection of prostate-specific membrane antigen (PSMA)-positive lesions with PET in adults with prostate cancer (PCa ...

New approval provides French hospitals and clinics with access to a proven PSMA-PET imaging agent MELBOURNE, Australia, April 29, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX ...

This approval enables healthcare providers in Sweden to offer PSMA-PET [3] imaging using a clinically validated gallium-based radiopharmaceutical. Illuccix, after radiolabelling with gallium-68 ...